Evidence map›Paper›PMID 29172675›Full record

ReviewThe British journal of radiology2018

Immune-related tumour response assessment criteria: a comprehensive review.

Bhanusupriya Somarouthu, Susanna I Lee, Trinity Urban, Cheryl A Sadow, Gordon J Harris, Avinash Kambadakone

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The British journal of radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 4 pooled it
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 4 syntheses or guidelines pooled it, 85 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Exploring the efficacy of nivolumab and ipilimumab in renal cell carcinoma: insights from a district hospital cohort study.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. [Chinese multidisciplinary expert consensus on combined immunotherapy for hepatocellular carcinoma(2023 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Bhanusupriya Somarouthu1 Tumor Imaging Metrics Core, Dana-Farber/Harvard Cancer Centre , Boston, MA , USA.
Susanna I Lee2 Department of Radiology, Massachusetts General Hospital , Boston, MA , USA.
Trinity Urban1 Tumor Imaging Metrics Core, Dana-Farber/Harvard Cancer Centre , Boston, MA , USA.
Cheryl A Sadow3 Department of Radiology, Brigham and Women's Hospital , Boston, MA , USA.
Gordon J Harris1 Tumor Imaging Metrics Core, Dana-Farber/Harvard Cancer Centre , Boston, MA , USA.
Avinash Kambadakone2 Department of Radiology, Massachusetts General Hospital , Boston, MA , USA.
Massachusetts General Hospital · USBrigham and Women's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Growing emphasis on precision medicine in oncology has led to increasing use of targeted therapies that encompass a spectrum of drug classes including angiogenesis inhibitors, immune modulators, signal transduction inhibitors, DNA damage modulators, hormonal agents etc. Immune therapeutic drugs constitute a unique group among the novel therapeutic agents that are transforming cancer treatment, and their use is rising. The imaging manifestations in patients on immune therapies appear to be distinct from those typically seen with conventional cytotoxic therapies. Patients on immune therapies may demonstrate a delayed response, transient tumour enlargement followed by shrinkage, stable size, or initial appearance of new lesions followed by stability or response. These newer patterns of response to treatment have rendered conventional criteria such as World Health Organization and response evaluation criteria in solid tumours suboptimal in monitoring changes in tumour burden. As a consequence, newer imaging response criteria such as immune-related response evaluation criteria in solid tumours and immune-related response criteria are being implemented in many trials to effectively monitor patients on immune therapies. In this review, we discuss the traditional and new imaging response criteria for evaluation of solid tumours, review the outcomes of various articles which compared traditional criteria with the new immune-related criteria and discuss pseudo-progression and immune-related adverse events.

Indexed as

Diagnostic ImagingHumansImmunotherapyNeoplasmsPrecision MedicineResponse Evaluation Criteria in Solid Tumors

Identifiers

PMID29172675
PMCPMC5966001
OpenAlexW2768457211

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.